Ultragenyx
$ 23.30
-2.55%
10 Apr - close price
- Market Cap 2,350,765,000 USD
- Current Price $ 23.30
- High / Low $ 24.13 / 23.06
- Stock P/E N/A
- Book Value -0.83
- EPS -6.02
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -6.08 %
- 52 Week High 42.37
- 52 Week Low 18.29
About
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Analyst Target Price
$52.45
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-05 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.4 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 | -2.33 |
| Estimated EPS | -1.15 | -1.21 | -1.32 | -1.64 | -1.27 | -1.47 | -1.69 | -1.73 | -1.62 | -2.08 | -2.07 | -1.98 |
| Surprise | -0.14 | -0.6 | 0.15 | 0.07 | -0.12 | 0.07 | 0.17 | -0.3 | 0.1 | -0.15 | -0.18 | -0.35 |
| Surprise Percentage | -12.1739% | -49.5868% | 11.3636% | 4.2683% | -9.4488% | 4.7619% | 10.0592% | -17.341% | 6.1728% | -7.2115% | -8.6957% | -17.6768% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RARE
2026-04-09 20:10:29
The FDA has accepted Ultragenyx's resubmitted Biologics License Application (BLA) for UX111, a gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA), setting the PDUFA action date for September 19, 2026. This resubmission addresses previous concerns related to manufacturing and controls, and includes updated long-term clinical data showing meaningful neurodevelopmental gains and a well-tolerated safety profile in treated children. Ultragenyx views this acceptance as a significant step towards providing the first-ever therapy for Sanfilippo syndrome Type A.
2026-04-09 18:10:29
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently purchased between $1,001 and $15,000 worth of shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on March 3rd, as disclosed in an April 7th filing. Ultragenyx Pharmaceutical's stock traded up 2.4% to $23.70, giving the company a market capitalization of $2.33 billion despite missing recent quarterly EPS expectations and remaining loss-making. Analysts have a "Moderate Buy" consensus rating with a target price of $60.47, while insiders have sold a significant number of shares recently, and institutional investors hold nearly 98% of the stock.
2026-04-06 20:10:14
Levi & Korsinsky, LLP is reminding investors of Ultragenyx Pharmaceutical Inc. about a pending class action lawsuit with a lead plaintiff deadline of April 6, 2026. The lawsuit alleges securities fraud between August 3, 2023, and December 26, 2025, due to misleading statements regarding the potential of setrusumab, which led to a significant stock price drop after Phase III studies failed to meet primary endpoints. Investors who suffered losses during this period may be entitled to compensation without out-of-pocket costs.
2026-04-06 18:09:47
Shares of Ultragenyx Pharmaceutical (RARE) increased 5% after the FDA accepted its resubmitted biologics license application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). The regulatory body set a target action date of September 19, 2026, and if approved, UX111 would be the first therapy for MPS IIIA, a rare and fatal lysosomal storage disorder. The resubmission addresses previous manufacturing and control issues cited in a Complete Response Letter and includes updated clinical data.
2026-04-06 15:09:12
Bragar Eagel & Squire, P.C. announced that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) regarding alleged materially false and misleading statements concerning its Phase III Orbit and Cosmic Studies. Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, are urged to contact the firm by the April 6, 2026, lead plaintiff deadline if they suffered losses. The lawsuit stems from a significant stock drop after Ultragenyx announced its studies did not achieve statistical significance for reducing fracture rates.
2026-04-06 13:09:12
Faruqi & Faruqi, LLP is reminding investors of Ultragenyx Pharmaceutical (NASDAQ: RARE) about the April 6, 2026, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Ultragenyx and its executives made misleading statements regarding the effectiveness of setrusumab for Osteogenesis Imperfecta, particularly concerning the Phase III Orbit and Cosmic studies, which ultimately failed to meet primary endpoints. Investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, and suffered losses are encouraged to contact the law firm.
